Can a slow start with CBD oil tame Hard-to-Control seizures?
NCT ID NCT07728097
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial tests whether a gradual dosing schedule of cannabidiol oral solution (CBD-OS) can help reduce seizures in adults with Lennox-Gastaut syndrome, a severe form of epilepsy. Participants will take CBD oil alongside their usual seizure medications. The study measures how many people experience at least a 50% drop in major motor seizures over 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cannabidiol oral solution (CBD-OS), a purified CBD oil taken by mouth
- What this could lead to
- If successful, this could offer a better-tolerated way to add CBD to existing seizure medications for adults with Lennox-Gastaut syndrome.
- What could go wrong
- This is an open-label trial with no placebo group, so results may be less reliable. CBD can cause side effects like drowsiness, diarrhea, and liver enzyme changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Louisiana State University Health Sciences Center New Orleans
New Orleans, Louisiana, 70112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which treatment tames LGS seizures better: surgery or more meds?
- Lifeline for kids with severe epilepsy: drug access extended
- Brain pacemaker shows promise for rare childhood epilepsy
- Brain implant shows promise for Hard-to-Treat seizures in rare epilepsy
- New drug shows promise for rare, severe childhood epilepsy
- New epilepsy drug shows promise in long-term safety trial